Mr. Denise Faltischek reports

TILRAY MEDICAL GRANTED APPROVAL TO INTRODUCE THIRD MEDICAL CANNABIS PRODUCT IN PORTUGAL

Tilray Brands Inc. has made another milestone achievement in medical cannabis in Europe. Following the successful approval of Tilray Medical whole flower THC (tetrahydrocannabinol) 18 and approval for the first cannabis extract in Portugal earlier this year, Tilray Medical receives its second approval for a new medical cannabis extract in Portugal: Tilray Oral Solution THC10:CBD10, also known as Tilray Solucao Oral THC10:CBD10.

Denise Faltischek, chief strategy officer and head of international at Tilray Brand, said: "We are proud to have received approval for our Tilray Solucao Oral THC10:CBD10 product and expanding our medical cannabis offerings for patients in Portugal. This is a significant step towards meeting the critical needs of patient care and providing high-quality cannabis products and therapeutic options to those with specific medical conditions. The approval of this oral cannabis solution in Portugal is a testament to Tilray's global commitment to increasing safe and regulated access to medical cannabis products for patients in need."

Tilray Medical continues to be a global leader in the medical cannabis industry, offering a diverse portfolio of EU-GMP (European Union good manufacturing practice) certified medicinal cannabis products. With operations extending over 20 countries, Tilray Medical is dedicated to supporting medical cannabis patient care worldwide through quality products accessible through health care practitioners.

About Tilray Brands Inc.

Tilray Brands is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America that is changing people's lives for the better -- one person at a time -- by inspiring and empowering a worldwide community to live their very best life, enhanced by moments of connection and well-being.

We seek Safe Harbor.